Related references
Note: Only part of the references are listed.Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening environment
Maria Giustina Rotordam et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2021)
Pharmacologic treatment and SUDEP risk A nationwide, population-based, case-control study
Olafur Sveinsson et al.
NEUROLOGY (2020)
Simultaneous assessment of compound activity on cardiac Nav1.5 peak and late currents in an automated patch clamp platform
Donglin Guo et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2019)
Modernized Classification of Cardiac Antiarrhythmic Drugs
Ming Lei et al.
CIRCULATION (2018)
Predicting QRS and PR interval prolongations in humans using nonclinical data
L. Bergenholm et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Sodium Channel Blockers in the Treatment of Epilepsy
Martin J. Brodie
CNS DRUGS (2017)
Cardiovascular adverse effects of phenytoin
B. Guldiken et al.
JOURNAL OF NEUROLOGY (2016)
Properties of human brain sodium channel α-subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine
Xin Qiao et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
The evaluation and management of drug effects on cardiac conduction (PR and QRS Intervals) in clinical development
Adel Nada et al.
AMERICAN HEART JOURNAL (2013)
Inhibition of Late Sodium Current by Mexiletine: A Novel Pharmotherapeutical Approach in Timothy Syndrome
Yuanfeng Gao et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2013)
Drug-induced Brugada syndrome
Yoshino Minoura et al.
JOURNAL OF ARRHYTHMIA (2013)
Effect of lamotrigine on the PR interval in healthy subjects
Ruth Dixon et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
On the relationship between block of the cardiac Na+ channel and drug-induced prolongation of the QRS complex
A. R. Harmer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine
S. Svalheim et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Sodium Channel (Dys)Function and Cardiac Arrhythmias
Carol Ann Remme et al.
CARDIOVASCULAR THERAPEUTICS (2010)
A Prospective Open-Label Trial of Lamotrigine Monotherapy in Children and Adolescents with Bipolar Disorder
Joseph Biederman et al.
CNS NEUROSCIENCE & THERAPEUTICS (2010)
Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1
E. L. Logigian et al.
NEUROLOGY (2010)
RECENT ADVANCES IN ADJUNCTIVE THERAPY FOR EPILEPSY: FOCUS ON SODIUM CHANNEL BLOCKERS AS THIRD-GENERATION ANTIEPILEPTIC DRUGS
D. Vohora et al.
DRUGS OF TODAY (2010)
Subtype-selective targeting of voltage-gated sodium channels
Steve England et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Cardiac function and antiepileptic drug treatment in the elderly: A comparison between lamotrigine and sustained-release carbamazepine
Erik Saetre et al.
EPILEPSIA (2009)
Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects
Ruth Dixon et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus
Chun-Yao Lee et al.
EPILEPSIA (2008)
Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre
Frida Persson et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents
BR Danielsson et al.
EPILEPSY RESEARCH (2005)
Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy
LJ Hirsch et al.
NEUROLOGY (2004)
Overview of the voltage-gated sodium channel family
FH Yu et al.
GENOME BIOLOGY (2003)
Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome
W Shimizu et al.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (2000)
Share Paper
